At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 147 enrolled
Drug / intervention
Ixekizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind and Placebo-Controlled 16-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Chinese Patients With Radiographic Axial Spondyloarthritis
In Brief
A Phase 3 clinical trial evaluating Ixekizumab and Placebo for Spondyloarthritis. Completed, enrolled 147 participants across 19 sites.
Detailed Summary
The main purpose of this study is to evaluate the efficacy and safety of ixekizumab in Chinese participants with radiographic axial spondyloarthritis (r-axSpA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpondyloarthritis
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedFeb 2020
Enrollment StartApr 2020
Primary CompletionMar 2021
Study CompletionMar 2022
TodayJul 2026
First PostedFeb 26, 2020
Enrollment StartApr 10, 2020
Primary CompletionMar 31, 2021
Study CompletionMar 17, 2022
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 6.4 years ago
Interventions
Ixekizumabdrug
Administered SC
Placebodrug
Administered SC